Follow the Ascendis Pharma A/S stock price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €16.3bn. The latest transaction was filed on 3 September 2026 (Cession). Among the most active insiders: BIENAIME JEAN JACQUES. All data is free.
11
Insider Decl.
n/a
Thresholds
€671,606
9 ops.
Buy Volume
€4m
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Ascendis Pharma A/S Strong Buy (bullish), based on 19 analysts. Average price target: US$313.08.
42Σ signal
Buys €671,606€4m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 15,499 of 29,062 companies
50.2
score / 100
Value
34
Quality
66
FCF yld0.3%
Earn yld-1.4%
EV/EBITDA·
ROE119%
Gross mgn87%
Net mgn-32%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
19,460 shares@ US$238.4903100.0% of flowOrdinary SharesSEC:0001610717-26-000159:0
11 of 11 declarations
Acerca de Ascendis Pharma A/S
Ascendis Pharma A/S es una empresa biofarmacéutica centrada en el desarrollo de tratamientos innovadores para enfermedades endocrinas y otras afecciones médicas. Utiliza su plataforma tecnológica de fármacos para crear terapias basadas en péptidos.